If you are interested in joining an organization that is focused on hard work, excellence, and scientific advancement, please reach out to us using the form below.
Stuart Therapeutics controls the exclusive worldwide rights to the PolyCol technology and associated patents for human therapeutic use in ophthalmology through license. We are committed to the development of important new innovations in therapeutics for chronic ophthalmic indications and are interested in strategic partner relationships that will extend and accelerate our impact.
Stuart Therapeutics continues to expand the set of ophthalmology opportunities for PolyCol. The company is recruiting for its Phase 3 clinical trial for its first drug candidate, ST-100 (vezocolmitide) for Dry Eye Disease. The company has partnered with Aju Pharm of South Korea for ST-100 in certain Southeast Asian markets. In October of 2023, Stuart Therapeutics joined forces with Glaukos Corporation in an exclusive worldwide license to develop PolyCol in glaucoma neuroprotection. Stuart continues to advance this important technology through research and development into its mechanism of action, potential therapeutic indications, and clinical trials.